HEY NOW: Past-due medical bills are the reason 59 percent of Americans are contacted by a debt collector and 16 percent of Americans’ credit reports include medical debt — about $81 billion total. Yale researchers reviewed more than 8.9 million ER bills, they discovered that 22 percent of privately insured patients were treated by out-of-network doctors.

SHORT READ: According to DRG “physician-pharma rep engagement has declined significantly in the past year, with in-person interaction, traditionally pharma’s main commercial lever, accounting for most of the drop. Remote engagement is not yet picking up the slack. Interest in remote use has declined as the novelty has worn off, but remains substantial”.

OPENING: Opening your own medical practice is a natural step in many people’s career paths, but it comes with many challenges. One of the most significant hurdles can simply be getting your name out there, and it can take time to build a decent patient list within your community. That’s why you can’t just sit around waiting for referrals. You need to get out there and market your new practice, ensuring that when people need your services, you’re the first place they think about. Here are some simple marketing tips for medical practices. 

KEY TAKEAWAY: According to a 2018 study from the Pew Research Center, two-thirds of American adults turn to Facebook for news, and a lot of people belong to Facebook groups for specific health conditions, but I have found an abundance of false information. This represents an opportunity for pharma, but they need to align processes around online health seeker needs.

SUMMARY: The CEOs of Abbvie, Bristol-Myers Squibb, Merck, Pfizer, Roche Pharmaceuticals, and Sanofi each contributed $15,600 to McConnell’s joint fundraising committee in the third quarter. Novo Nordisk Executive Vice President Doug Langa chipped in $10,000, Amgen CEO Robert Bradway gave $7,500, and Celgene CEO Mark Alles contributed $5,000. McConnell’s opposition to the bill comes after he had an exceptional quarter of fundraising from executives and PACs of pharmaceutical companies that could be forced to reduce the prices of their drugs under Medicare. Sigh..